Comprehensive Rural Health Services Project
Ballabgarh, Haryana, India
NCT Number: NCT01680679
Influenza viruses are significant causes of human illness and death in developed and developing countries. This study will measure the ability of influenza vaccine given to children in India to protect both the children and unimmunized persons around them from influenza. It will also determine whether the best time to immunize in a country like India that has both summer and winter outbreaks of influenza is in the fall, as is done now, or whether immunization should be in the spring to protect against influenza infections in the summer.
Looking for future studies?
Notify Me6 month–10 year
All sexes
Interventional
Phase 4
Ballabgarh, Haryana, India
Although influenza vaccines are used routinely in the United States, including in young children, influenza vaccines have not seen widespread use in India. This is likely contributed to by the lack of information from India about disease burden due to influenza and because influenza vaccines have not been tested for efficacy in India. In addition, because young children are thought to be important in the spread of influenza in families, it is possible immunization of children against influenza will reduce influenza infections among older children and adults in the home. The study described here is an extension of an earlier study (ClinicalTrials.gov NCT00934245) that tested the use of immunization against influenza in the fall. The current study will administer influenza vaccine in the spring prior to the summer monsoon rains that are associated with peaks of influenza activity in parts of India. Reduction of influenza infections among the influenza immunized children and their household members will be compared to the children and household members in the control vaccine group.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion in either vaccine group (TIV or IPV) will require ages 6 months through 10 years of age.
All individuals in enrolled households will be eligible for enrollment into surveillance arm.
Exclusion criteria
Exclusion criteria
from the vaccine groups includes known allergy to eggs, or hypersensitivity to other components of the vaccines.
Time frame: 1 year
Time frame: 1 year
University of Colorado, Denver
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07737106
Infections, Influenza
Bayan Nur, Inner Mongolia, China
View Trial DetailsNCT06518577
Infections, Influenza
Phoenix, Arizona, United States
View Trial DetailsNCT06560151
Infections, Influenza
Atlanta, Georgia, United States
View Trial Details